My research focuses on developing new ways to measure cellular events to advance our understanding of cellular signaling and its role in physiology and disease.
I am a highly experienced electrophysiologist, biochemist, and pharmacologist. Beginning with my undergraduate studies and continuing throughout my career, I have studied membrane-delimited signal transduction systems. I have over a two decades of experience designing, developing, and implementing high-throughput screens (HTS) with an emphasis on ion channels, transporters, and GPCRs. Beginning in 1998 at Bristol-Myers Squibb, I began developing novel methodologies for discovering and characterizing modulators ion channels, transporters and GPCRs. These methodologies include the thallium flux assay which has become the primary means of high-throughput screening for potassium channel modulators in both academia and the pharmaceutical industry. At BMS I led a group of scientist responsible for discovery and development of preclinical ion channel modulators focused on CNS disorders. Since 2004, I have continued this work as the founder/director of the Vanderbilt Institute of Chemical Biology’s (VICB) HTS Facility (2004-present), Director of the Vanderbilt MLSCN screening center for GPCRs, Ion Channels, and Transporters (2005-2008), and Director of Molecular Pharmacology for the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD, 2005-2010). I have substantial experience and expertise in hits-to-leads and lead optimization for CNS ion channel, transporters, and GPCR targets including >5 late-stage preclinical and clinical development candidates. Recently, I have founded a small business, WaveFront Biosciences, focused on the development of a new generation of instrumentation, software, and reagents to advance our ability to rapidly detect and characterize modulators of ion channels, transporters and GPCRs.